<DOC>
	<DOCNO>NCT01734395</DOCNO>
	<brief_summary>The purpose study demonstrate change attention measure correlate change caregiver 's burden treatment galantamine .</brief_summary>
	<brief_title>A Study Show That Change Attention Measure Correlated With Changes Caregiver 's Burden After Treatment With Galantamine Patients With Alzheimer 's Disease</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , prospective ( participant first identify follow forward time pass ) , observational ( study investigators/ physician observe patient measure outcome ) , multi-center ( study conduct multiple site ) study . The study mainly consist 2 phase include , screen phase ( 14 day administration study medication ) treatment phase ( 16 week ) . In treatment phase , patient receive galantamine 8 mg/day first 4 week later dose increase 24mg ( tolerable ) . Safety evaluation include assessment adverse event . The total duration study 18 week .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<criteria>Alzheimer 's disease accord criterion Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) , National Institute Neurological Communicative Diseases StrokeAlzheimer 's Disease Related Disorders Association ( NINCDSADRDA ) Measuring standard : KMMSE 10 24 Patient reliable Guardian Patients brain tumor , nerve syphilis , meningitis , encephalitis , epilepsy Major psychiatric patient major depression schizophrenia Patients treatmentresistant gastric peptic ulcer Patients clinically serious hepatic , renal , lung , endocrinal metabolic disease ( thyroid , parathyroid , pituitary , renal failure , diabetes mellitus )</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>Caregiver 's Burden Alzheimer 's disease</keyword>
	<keyword>Galantamine</keyword>
	<keyword>Razadyne</keyword>
	<keyword>Reminyl</keyword>
</DOC>